Compare Biogen Inc (BIIB) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Seagate Technology Holdings PLC — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Seagate Technology Holdings PLC trades at $814.43 (market cap $198.72B). The key difference: Seagate Technology Holdings PLC is far larger — about 7× Biogen Inc's market cap, and Seagate Technology Holdings PLC pays a 0.34% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | STX | |
|---|---|---|
Market Cap | $28.34B | $198.72B |
Sector | Health | Technology |
52-Week High | $216.63 | $1.09K |
52-Week Low | $122.68 | $146.59 |
Enterprise Value | $30.62B | $201.75B |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
STX trades at $860.66, down 5.46% over 24 hours, with a bearish technical signal and elevated valuation ratios (P/E 81.66, P/S 17.61). Recent earnings beats (Q1 2026 EPS $4.10 vs. $3.51 expected) and strong revenue growth to $9.10B in 2025 highlight operational momentum, though negative shareholder equity and high debt pose balance sheet concerns. Analyst consensus remains bullish with a $987.86 price target, supported by AI-driven storage demand upgrades from Wells Fargo on July 10, 2026.
Outlook: STX benefits from AI infrastructure tailwinds and earnings consistency, but high leverage and volatile cash flows present risks. The stock offers upside to analyst targets if execution continues, yet investors face sensitivity to memory market cycles and debt servicing challenges amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
